Iovance Biotherapeutics, Inc. (IOVA) Raises 2026 Revenue Guidance to $410—$420M

Iovance raised its 2026 total revenue guidance to $410—$420M, up ~$55M at the midpoint from $350—$370M, citing strong U.S. demand for Amtagvi and Proleukin. The update implies nearly 60% annual revenue growth.Material DetailsContext by AI AnalystThis is a mid-cycle confirmation of accelerating comm…